N/A
Manufactured by Janssen Pharmaceuticals Inc.
24,470 FDA adverse event reports analyzed
Last updated: 2026-04-14
ESKETAMINE HYDROCHLORIDE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Janssen Pharmaceuticals Inc.. The most commonly reported adverse reactions for ESKETAMINE HYDROCHLORIDE include DISSOCIATION, SEDATION, SUICIDAL IDEATION, DRUG INEFFECTIVE, NAUSEA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for ESKETAMINE HYDROCHLORIDE.
Out of 15,775 classified reports for ESKETAMINE HYDROCHLORIDE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 24,470 FDA FAERS reports that mention ESKETAMINE HYDROCHLORIDE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DISSOCIATION, SEDATION, SUICIDAL IDEATION, DRUG INEFFECTIVE, NAUSEA, DEPRESSION. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Janssen Pharmaceuticals Inc. in connection with ESKETAMINE HYDROCHLORIDE. Always verify the specific product and NDC with your pharmacist.